FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128861567> ?p ?o ?g. }

• W3128861567 endingPage "204062072199055" @default.
• W3128861567 startingPage "204062072199055" @default.
• W3128861567 abstract "The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic evolution include the Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors. Ibrutinib was the first-in-class drug which was initially approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory and later for patients with treatment-naïve CLL. Despite encouraging efficacy outcomes, its use has been associated with cardiovascular and gastrointestinal toxicities likely due to off-target inhibition of ITK, TEC and EGFR family kinases. The next generation of BTK inhibitors was developed to be more selective with less off-target inhibition with the prospect to improve tolerability without compromising efficacy. Acalabrutinib, a selective covalent BTK inhibitor, is a second generation BTK inhibitor. The focus of this review is on two major phase III trials that resulted in the FDA approval of acalabrutinib in 2019. The ELEVATE TN trial investigated acalabrutinib with or without obintuzumab versus chlorambucil–obinutuzumab in older and frail patients with previously untreated CLL. The ASCEND trial explored acalabrutinib versus chemoimmunotherapy in patients with relapsed/refractory CLL. Both trials demonstrated superiority of the acalabrutinib-containing arms in terms of both efficacy and tolerability. Unfortunately, the availability of new generation BTK inhibitors has not resulted in mitigating the financial toxicities associated with these potentially life-long treatments." @default.
• W3128861567 created "2021-02-15" @default.
• W3128861567 creator A5068715900 @default.
• W3128861567 creator A5082487188 @default.
• W3128861567 date "2021-01-01" @default.
• W3128861567 modified "2023-10-16" @default.
• W3128861567 title "The role of acalabrutinib in adults with chronic lymphocytic leukemia" @default.
• W3128861567 cites W2108206643 @default.
• W3128861567 cites W2120319857 @default.
• W3128861567 cites W2171771895 @default.
• W3128861567 cites W2233614027 @default.
• W3128861567 cites W2260369425 @default.
• W3128861567 cites W2316021978 @default.
• W3128861567 cites W2514059094 @default.
• W3128861567 cites W2558640761 @default.
• W3128861567 cites W2589238872 @default.
• W3128861567 cites W2774522106 @default.
• W3128861567 cites W2777750326 @default.
• W3128861567 cites W2787916641 @default.
• W3128861567 cites W2806627663 @default.
• W3128861567 cites W2902484351 @default.
• W3128861567 cites W2902706178 @default.
• W3128861567 cites W2922286357 @default.
• W3128861567 cites W2945468305 @default.
• W3128861567 cites W2946882253 @default.
• W3128861567 cites W2948436219 @default.
• W3128861567 cites W2954965074 @default.
• W3128861567 cites W2966190920 @default.
• W3128861567 cites W2973195462 @default.
• W3128861567 cites W2979710073 @default.
• W3128861567 cites W2980937306 @default.
• W3128861567 cites W2983802128 @default.
• W3128861567 cites W2984031213 @default.
• W3128861567 cites W2987552010 @default.
• W3128861567 cites W3012874730 @default.
• W3128861567 cites W3016538158 @default.
• W3128861567 cites W3029637120 @default.
• W3128861567 cites W3082899459 @default.
• W3128861567 doi "https://doi.org/10.1177/2040620721990553" @default.
• W3128861567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7871059" @default.
• W3128861567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33613932" @default.
• W3128861567 hasPublicationYear "2021" @default.
• W3128861567 type Work @default.
• W3128861567 sameAs 3128861567 @default.
• W3128861567 citedByCount "4" @default.
• W3128861567 countsByYear W31288615672021 @default.
• W3128861567 countsByYear W31288615672023 @default.
• W3128861567 crossrefType "journal-article" @default.
• W3128861567 hasAuthorship W3128861567A5068715900 @default.
• W3128861567 hasAuthorship W3128861567A5082487188 @default.
• W3128861567 hasBestOaLocation W31288615671 @default.
• W3128861567 hasConcept C126322002 @default.
• W3128861567 hasConcept C143998085 @default.
• W3128861567 hasConcept C170493617 @default.
• W3128861567 hasConcept C197934379 @default.
• W3128861567 hasConcept C2776694085 @default.
• W3128861567 hasConcept C2776755627 @default.
• W3128861567 hasConcept C2777866208 @default.
• W3128861567 hasConcept C2777938653 @default.
• W3128861567 hasConcept C2778375690 @default.
• W3128861567 hasConcept C2778461978 @default.
• W3128861567 hasConcept C2779878957 @default.
• W3128861567 hasConcept C2780790343 @default.
• W3128861567 hasConcept C42362537 @default.
• W3128861567 hasConcept C535046627 @default.
• W3128861567 hasConcept C71924100 @default.
• W3128861567 hasConcept C90059517 @default.
• W3128861567 hasConcept C98274493 @default.
• W3128861567 hasConceptScore W3128861567C126322002 @default.
• W3128861567 hasConceptScore W3128861567C143998085 @default.
• W3128861567 hasConceptScore W3128861567C170493617 @default.
• W3128861567 hasConceptScore W3128861567C197934379 @default.
• W3128861567 hasConceptScore W3128861567C2776694085 @default.
• W3128861567 hasConceptScore W3128861567C2776755627 @default.
• W3128861567 hasConceptScore W3128861567C2777866208 @default.
• W3128861567 hasConceptScore W3128861567C2777938653 @default.
• W3128861567 hasConceptScore W3128861567C2778375690 @default.
• W3128861567 hasConceptScore W3128861567C2778461978 @default.
• W3128861567 hasConceptScore W3128861567C2779878957 @default.
• W3128861567 hasConceptScore W3128861567C2780790343 @default.
• W3128861567 hasConceptScore W3128861567C42362537 @default.
• W3128861567 hasConceptScore W3128861567C535046627 @default.
• W3128861567 hasConceptScore W3128861567C71924100 @default.
• W3128861567 hasConceptScore W3128861567C90059517 @default.
• W3128861567 hasConceptScore W3128861567C98274493 @default.
• W3128861567 hasLocation W31288615671 @default.
• W3128861567 hasLocation W31288615672 @default.
• W3128861567 hasLocation W31288615673 @default.
• W3128861567 hasOpenAccess W3128861567 @default.
• W3128861567 hasPrimaryLocation W31288615671 @default.
• W3128861567 hasRelatedWork W2207067957 @default.
• W3128861567 hasRelatedWork W2284975440 @default.
• W3128861567 hasRelatedWork W2468505734 @default.
• W3128861567 hasRelatedWork W2902300122 @default.
• W3128861567 hasRelatedWork W3014040379 @default.
• W3128861567 hasRelatedWork W3016355356 @default.
• W3128861567 hasRelatedWork W3203396887 @default.
• W3128861567 hasRelatedWork W384535638 @default.

• next